Marinus Pharmaceuticals (MRNS) PT Lowered to $22 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Marinus Pharmaceuticals (MRNS) PT Lowered to $22 at Jefferies
November 9, 2022 7:59 AM EST
Oppenheimer analyst Jay Olson lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $12.00 (from $23.00) while maintaining a Outperform rating.... More
November 9, 2022 7:15 AM EST
H.C. Wainwright analyst Douglas Tsao lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $27.00 (from $38.00) while maintaining a Buy rating.... More
November 8, 2022 5:40 AM EST
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 2,105,264 shares of common stock at a price of $4.749 per pre-funded warrant, for gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and offering expenses payable by Marinus. The purchase price per share of each pre-funded warrant... More
November 7, 2022 4:23 PM EST
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the offering are being offered by Marinus. In addition, Marinus... More
